Epigenetics of ovarian cancer: From the lab to the clinic

Gynecologic Oncology

Volumn 118, Issue 1, 2010, Pages 81-87

  Asadollahi, Reza ^a   Hyde, Caroline A C ^a   Zhong, Xiao Yan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

DNA methylation; Histone modification; MicroRNA; Ovarian cancer; Prognosis; Treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; CARBOPLATIN; DNA METHYLTRANSFERASE INHIBITOR; GEMCITABINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; PACLITAXEL; VALPROIC ACID; VORINOSTAT;

CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENOME IMPRINTING; HUMAN; METHYLATION; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MODIFICATION; REVIEW;

EPIGENESIS, GENETIC; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 77953288216     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.03.015     Document Type: Review

References (137)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249
2. Fung-Kee-Fung M., Oliver T., Elit L., Oza A., Hirte H.W., and Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14 (2007) 195-208
3. Bast Jr. R.C., Hennessy B., and Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9 (2009) 415-428
4. Balch C., Fang F., Matei D.E., Huang T.H., and Nephew K.P. Minireview: epigenetic changes in ovarian cancer. Endocrinology 150 (2009) 4003-4011
5. Chiang P.K., Gordon R.K., Tal J., Zeng G.C., Doctor B.P., Pardhasaradhi K., et al. S-Adenosylmethionine and methylation. FASEB J 10 (1996) 471-480
6. Singal R., and Ginder G.D. DNA methylation. Blood 93 (1999) 4059-4070
7. Murphy S.K., and Jirtle R.L. Imprinted genes as potential genetic and epigenetic toxicologic targets. Environ Health Perspect 108 Suppl 1 (2000) 5-11
8. Antequera F., and Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A 90 (1993) 11995-11999
9. Costello J.F., and Plass C. Methylation matters. J Med Genet 38 (2001) 285-303
10. Monk M., Boubelik M., and Lehnert S. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. Development 99 (1987) 371-382
11. Kafri T., Ariel M., Brandeis M., Shemer R., Urven L., McCarrey J., et al. Developmental pattern of gene-specific DNA methylation in the mouse embryo and germ line. Genes Dev 6 (1992) 705-714
12. Issa J.P. CpG-island methylation in aging and cancer. Curr Top Microbiol Immunol 249 (2000) 101-118
13. Tsou J.A., Hagen J.A., Carpenter C.L., and Laird-Offringa I.A. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21 (2002) 5450-5461
14. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24 (2000) 132-138
15. Shi H., Yan P.S., Chen C.M., Rahmatpanah F., Lofton-Day C., Caldwell C.W., et al. Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res 62 (2002) 3214-3220
16. Suzuki H., Gabrielson E., Chen W., Anbazhagan R., van Engeland M., Weijenberg M.P., et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31 (2002) 141-149
17. Barton C.A., Hacker N.F., Clark S.J., and O'Brien P.M. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109 (2008) 129-139
18. Sellar G.C., Watt K.P., Rabiasz G.J., Stronach E.A., Li L., Miller E.P., et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 34 (2003) 337-343
19. Teodoridis J.M., Hall J., Marsh S., Kannall H.D., Smyth C., Curto J., et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65 (2005) 8961-8967
20. Zhang J., Ye F., Chen H.Z., Ye D.F., Lu W.G., and Xie X. Deletion of OPCML gene and promoter methylation in ovarian epithelial carcinoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28 (2006) 173-177
21. Agathanggelou A., Honorio S., Macartney D.P., Martinez A., Dallol A., Rader J., et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20 (2001) 1509-1518
22. Yoon J.H., Dammann R., and Pfeifer G.P. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 94 (2001) 212-217
23. Yu Y., Xu F., Peng H., Fang X., Zhao S., Li Y., et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 96 (1999) 214-219
24. Yu Y., Fujii S., Yuan J., Luo R.Z., Wang L., Bao J., et al. Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci 983 (2003) 268-277
25. Feng W., Marquez R.T., Lu Z., Liu J., Lu K.H., Issa J.P., et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112 (2008) 1489-1502
26. Kwong J., Lee J.Y., Wong K.K., Zhou X., Wong D.T., Lo K.W., et al. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8 (2006) 268-278
27. Petrocca F., Iliopoulos D., Qin H.R., Nicoloso M.S., Yendamuri S., Wojcik S.E., et al. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res 66 (2006) 10287-10291
28. Chien J., Staub J., Avula R., Zhang H., Liu W., Hartmann L.C., et al. Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 24 (2005) 5089-5100
29. Press J.Z., De Luca A., Boyd N., Young S., Troussard A., Ridge Y., et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8 (2008) 17
30. Milde-Langosch K., Ocon E., Becker G., and Loning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 79 (1998) 61-65
31. Balch C., Huang T.H., Brown R., and Nephew K.P. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191 (2004) 1552-1572
32. Esteller M., Corn P.G., Baylin S.B., and Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res 61 (2001) 3225-3229
33. Baldwin R.L., Nemeth E., Tran H., Shvartsman H., Cass I., Narod S., et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60 (2000) 5329-5333
34. Wilcox C.B., Baysal B.E., Gallion H.H., Strange M.A., and DeLoia J.A. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159 (2005) 114-122
35. Akahira J., Sugihashi Y., Ito K., Niikura H., Okamura K., and Yaegashi N. Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer. Cancer Sci 95 (2004) 40-43
36. Terasawa K., Sagae S., Toyota M., Tsukada K., Ogi K., Satoh A., et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 10 (2004) 2000-2006
37. Kaneuchi M., Sasaki M., Tanaka Y., Shiina H., Yamada H., Yamamoto R., et al. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 104 (2005) 1924-1930
38. Kaneuchi M., Sasaki M., Tanaka Y., Shiina H., Verma M., Ebina Y., et al. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316 (2004) 1156-1162
39. Makarla P.B., Saboorian M.H., Ashfaq R., Toyooka K.O., Toyooka S., Minna J.D., et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11 (2005) 5365-5369
40. Ma L., Guo Q., Ma Y., Liu F.R., and Shen X.Y. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers. Eur J Gynaecol Oncol 30 (2009) 370-374
41. Cheng P., Schmutte C., Cofer K.F., Felix J.C., Yu M.C., and Dubeau L. Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br J Cancer 75 (1997) 396-402
42. Rose S.L., Fitzgerald M.P., White N.O., Hitchler M.J., Futscher B.W., De Geest K., et al. Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol 102 (2006) 319-324
43. Gupta A., Godwin A.K., Vanderveer L., Lu A., and Liu J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 63 (2003) 664-673
44. Czekierdowski A., Czekierdowska S., Wielgos M., Smolen A., Kaminski P., and Kotarski J. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett 27 (2006) 381-386
45. Litkouhi B., Kwong J., Lo C.M., Smedley III J.G., McClane B.A., Aponte M., et al. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9 (2007) 304-314
46. Honda H., Pazin M.J., Ji H., Wernyj R.P., and Morin P.J. Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem 281 (2006) 21433-21444
47. Menendez L., Benigno B.B., and McDonald J.F. L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol Cancer 3 (2004) 12
48. Laird P.W. The power and the promise of DNA methylation markers. Nat Rev Cancer 3 (2003) 253-266
49. Widschwendter M., Apostolidou S., Jones A.A., Fourkala E.O., Arora R., Pearce C.L., et al. HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int J Cancer 125 (2009) 2214-2218
50. Ibanez de Caceres I., Battagli C., Esteller M., Herman J.G., Dulaimi E., Edelson M.I., et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64 (2004) 6476-6481
51. Su H.Y., Lai H.C., Lin Y.W., Chou Y.C., Liu C.Y., and Yu M.H. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 124 (2009) 387-393
52. Mori T., O'Day S.J., Umetani N., Martinez S.R., Kitago M., Koyanagi K., et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 23 (2005) 9351-9358
53. Teschendorff A.E., Menon U., Gentry-Maharaj A., Ramus S.J., Gayther S.A., Apostolidou S., et al. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 4 (2009) e8274
54. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., and Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96 (1999) 8681-8686
55. Goel A., Nagasaka T., Arnold C.N., Inoue T., Hamilton C., Niedzwiecki D., et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132 (2007) 127-138
56. Ogino S., Kawasaki T., Kirkner G.J., Ohnishi M., and Fuchs C.S. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 7 (2007) 72
57. Marsit C.J., Houseman E.A., Christensen B.C., Eddy K., Bueno R., Sugarbaker D.J., et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 66 (2006) 10621-10629
58. Suzuki M., Shigematsu H., Iizasa T., Hiroshima K., Nakatani Y., Minna J.D., et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 106 (2006) 2200-2207
59. Shen L., Ahuja N., Shen Y., Habib N.A., Toyota M., Rashid A., et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 94 (2002) 755-761
60. Roman-Gomez J., Jimenez-Velasco A., Agirre X., Castillejo J.A., Navarro G., Calasanz M.J., et al. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res 12 (2006) 4845-4850
61. Toyota M., Ahuja N., Suzuki H., Itoh F., Ohe-Toyota M., Imai K., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59 (1999) 5438-5442
62. Strathdee G., Appleton K., Illand M., Millan D.W., Sargent J., Paul J., et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158 (2001) 1121-1127
63. Ahluwalia A., Hurteau J.A., Bigsby R.M., and Nephew K.P. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol 82 (2001) 299-304
64. Tanemura A., Terando A.M., Sim M.S., van Hoesel A.Q., de Maat M.F., Morton D.L., et al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15 (2009) 1801-1807
65. Teodoridis J.M., Hardie C., and Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 268 (2008) 177-186
66. Wei S.H., Chen C.M., Strathdee G., Harnsomburana J., Shyu C.R., Rahmatpanah F., et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8 (2002) 2246-2252
67. Chen M.Y. Synergistic inhibition of ovarian cancer cell growth with demethylating agents and histone deacetylase inhibitors. Proc Amer Assoc Cancer Res 681 (2007)
68. Murphy S.K., Huang Z., Wen Y., Spillman M.A., Whitaker R.S., Simel L.R., et al. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 4 (2006) 283-292
69. Dammann R.H., Kirsch S., Schagdarsurengin U., Dansranjavin T., Gradhand E., Schmitt W.D., et al. Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma. Int J Oncol 36 (2009) 171-179
70. Turner B.M. Reading signals on the nucleosome with a new nomenclature for modified histones. Nat Struct Mol Biol 12 (2005) 110-112
71. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
72. Mutskov V., and Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 23 (2004) 138-149
73. Santos-Rosa H., Schneider R., Bannister A.J., Sherriff J., Bernstein B.E., Emre N.C., et al. Active genes are tri-methylated at K4 of histone H3. Nature 419 (2002) 407-411
74. Schneider R., Bannister A.J., Myers F.A., Thorne A.W., Crane-Robinson C., and Kouzarides T. Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat Cell Biol 6 (2004) 73-77
75. Abbosh P.H., Montgomery J.S., Starkey J.A., Novotny M., Zuhowski E.G., Egorin M.J., et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 66 (2006) 5582-5591
76. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 (1997) 595-606
77. Marzio G., Wagener C., Gutierrez M.I., Cartwright P., Helin K., and Giacca M. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 275 (2000) 10887-10892
78. Ammanamanchi S., Freeman J.W., and Brattain M.G. Acetylated sp3 is a transcriptional activator. J Biol Chem 278 (2003) 35775-35780
79. Gregoretti I.V., Lee Y.M., and Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338 (2004) 17-31
80. Jin K.L., Pak J.H., Park J.Y., Choi W.H., Lee J.Y., Kim J.H., et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol 19 (2008) 185-190
81. Izutsu N., Maesawa C., Shibazaki M., Oikawa H., Shoji T., Sugiyama T., et al. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol 32 (2008) 1227-1235
82. Mirza A., McGuirk M., Hockenberry T.N., Wu Q., Ashar H., Black S., et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21 (2002) 2613-2622
83. Fu Y., Campbell E.J., Shepherd T.G., and Nachtigal M.W. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 1 (2003) 569-576
84. Honda H., Pazin M.J., D'Souza T., Ji H., and Morin P.J. Regulation of the CLDN3 gene in ovarian cancer cells. Cancer Biol Ther 6 (2007) 1733-1742
85. Caslini C., Capo-chichi C.D., Roland I.H., Nicolas E., Yeung A.T., and Xu X.X. Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 25 (2006) 5446-5461
86. Cai K.Q., Caslini C., Capo-chichi C.D., Slater C., Smith E.R., Wu H., et al. Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. PLoS One 4 (2009) e6454
87. Schickel R., Boyerinas B., Park S.M., and Peter M.E. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27 (2008) 5959-5974
88. Gregory R.I., and Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 65 (2005) 3509-3512
89. Valencia-Sanchez M.A., Liu J., Hannon G.J., and Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20 (2006) 515-524
90. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 67 (2007) 8699-8707
91. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68 (2008) 425-433
92. Lee C.H., Subramanian S., Beck A.H., Espinosa I., Senz J., Zhu S.X., et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 4 (2009) e7314
93. Corney D.C., Hwang C.I., Matoso A., Vogt M., Flesken-Nikitin A., Godwin A.K., et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16 (2010) 1119-1128
94. Gadducci A., Cosio S., Tana R., and Genazzani A.R. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 69 (2009) 12-27
95. Wei S.H., Balch C., Paik H.H., Kim Y.S., Baldwin R.L., Liyanarachchi S., et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12 (2006) 2788-2794
96. Chou J.L., Su H.Y., Chen L.Y., Liao Y.P., Hartman-Frey C., Lai Y.H., et al. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 90 (2010) 414-425
97. Huang Y.W., Jansen R.A., Fabbri E., Potter D., Liyanarachchi S., Chan M.W., et al. Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep 22 (2009) 853-861
98. Bast R.C. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. J Clin Oncol 26 (2008) 3500 (Suppl.)
99. Chaudhry P., Srinivasan R., and Patel F.D. Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). Cancer Invest 27 (2009) 877-884
100. Swisher E.M., Gonzalez R.M., Taniguchi T., Garcia R.L., Walsh T., Goff B.A., et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 8 (2009) 48
101. Nicholson L.J., Smith P.R., Hiller L., Szlosarek P.W., Kimberley C., Sehouli J., et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 125 (2009) 1454-1463
102. Strathdee G., Vass J.K., Oien K.A., Siddiqui N., Curto-Garcia J., and Brown R. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol 97 (2005) 898-903
103. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer in press.
104. Lee P.S., Teaberry V.S., Bland A.E., Huang Z., Whitaker R.S., Baba T., et al. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer 126 (2010) 1378-1389
105. Li M., Balch C., Montgomery J.S., Jeong M., Chung J.H., Yan P., et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2 (2009) 34
106. Wei Y., Xia W., Zhang Z., Liu J., Wang H., Adsay N.V., et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47 (2008) 701-706
107. Weichert W., Denkert C., Noske A., Darb-Esfahani S., Dietel M., Kalloger S.E., et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10 (2008) 1021-1027
108. Boren T., Xiong Y., Hakam A., Wenham R., Apte S., Chan G., et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 113 (2009) 249-255
109. Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68 (2008) 10307-10314
110. Hede K. Small RNAs are raising big expectations. J Natl Cancer Inst 101 (2009) 840-841
111. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 (2007) 683-692
112. Esteller M. Epigenetics in cancer. N Engl J Med 358 (2008) 1148-1159
113. Li Y., Hu W., Shen D.Y., Kavanagh J.J., and Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol 200 177 (2009) e1-e9
114. Lenzi R., Frost P., and Abbruzzese J.L. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res 14 (1994) 247-251
115. Balch C., Yan P., Craft T., Young S., Skalnik D.G., Huang T.H., et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4 (2005) 1505-1514
116. Appleton K., Mackay H.J., Judson I., Plumb J.A., McCormick C., Strathdee G., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25 (2007) 4603-4609
117. Modesitt S.C., Sill M., Hoffman J.S., and Bender D.P. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109 (2008) 182-186
118. Mackay H. A phase II trial of the histone deacetylase inhibitor belinostat (PSC101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial. J Clin Oncol 26 (2008) 5518 (Suppl.)
119. Matei D.E., and Nephew K.P. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol 116 (2010) 195-201
120. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21 (1999) 103-107
121. Balch C., Montgomery J.S., Paik H.I., Kim S., Huang T.H., and Nephew K.P. New anti-cancer strategies: epigenetic therapies and biomarkers. Front Biosci 10 (2005) 1897-1931
122. Lyko F., and Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97 (2005) 1498-1506
123. Tam K.F., Liu V.W., Liu S.S., Tsang P.C., Cheung A.N., Yip A.M., et al. Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol 133 (2007) 331-341
124. Bai T., Tanaka T., Yukawa K., Maeda M., and Umesaki N. Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells. Oncol Rep 11 (2004) 661-665
125. Suzuki F., Akahira J., Miura I., Suzuki T., Ito K., Hayashi S., et al. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 99 (2008) 2365-2372
126. Zhang H., Zhang S., Cui J., Zhang A., Shen L., and Yu H. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust N Z J Obstet Gynaecol 48 (2008) 505-509
127. Meng C.F., Dai D.Q., and Guo K.J. Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP. Ai Zheng 27 (2008) 1251-1255
128. Arnold J.M., Cummings M., Purdie D., and Chenevix-Trench G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer 85 (2001) 1351-1358
129. Abdollahi A., Pisarcik D., Roberts D., Weinstein J., Cairns P., and Hamilton T.C. LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer. J Biol Chem 278 (2003) 6041-6049
130. Katsaros D., Cho W., Singal R., Fracchioli S., Rigault De La Longrais I.A., Arisio R., et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 94 (2004) 685-692
131. Horak P., Pils D., Haller G., Pribill I., Roessler M., Tomek S., et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3 (2005) 335-343
132. Torng P.L., Lin C.W., Chan M.W., Yang H.W., Huang S.C., and Lin C.T. Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma. Mol Cancer 8 (2009) 120
133. Barton C.A., Gloss B.S., Qu W., Statham A.L., Hacker N.F., Sutherland R.L., et al. Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival. Br J Cancer 102 (2010) 87-96
134. Zhang S., Wei L., Zhang A., Zhang L., and Yu H. RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines. OMICS 13 (2009) 307-311
135. Gao Y., Lou G., Zhang G.M., Sun X.W., Ma Y.Y., Yang Y.M., et al. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer. Int J Biol Markers 24 (2009) 83-89
136. Taniguchi T., Tischkowitz M., Ameziane N., Hodgson S.V., Mathew C.G., Joenje H., et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9 (2003) 568-574
137. Cheng W, Jiang Y, Liu C, Shen O, Tang W, Wang X. Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer. J Cancer Res Clin Oncol in press.